Back to today’s briefing

Story perspectives

Revolutionary HIV Vaccine Trial Launches in Africa

8/6/2025

28 2

Summary

Story summary

A groundbreaking clinical trial for a therapeutic HIV vaccine, backed by the Bill & Melinda Gates Foundation, is currently taking place in Africa with ReiThera’s innovative GRAd vector, targeting 120 participants. In tandem, Gilead Sciences' Lenacapavir, a promising biannual injectable for HIV prevention, is projected to reach a remarkable market value of $2.1 billion by 2031.

1 of 1

Story summary

A groundbreaking clinical trial for a therapeutic HIV vaccine, backed by the Bill & Melinda Gates Foundation, is currently taking place in Africa with ReiThera’s innovative GRAd vector, targeting 120 participants. In tandem, Gilead Sciences' Lenacapavir, a promising biannual injectable for HIV prevention, is projected to reach a remarkable market value of $2.1 billion by 2031.